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Abstract
Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma (NHL) that is
aggressive and incurable with existing therapies, presenting a significant unmet clini-
cal need.MCL occursmainly in elderly patients with comorbidities; thus, intense treat-
ment options including allogeneic stem cell transplantation (Allo-SCT) are not feasible.
New treatment options are emerging for this elderly/unfit treatment group, we there-
fore conducted a systematic review to determine whether they offered an advance
on the existing recommended treatment, R-CHOP. The search strategies to identify
MCL therapieswere designed to capture themost relevant studies from2013 to 2020.
Following preferred reporting items for systematic reviews and meta-analyses and
population,interventions, observations and study design analysis, R-CHOP, ibrutinib
and bendamustine plus rituximab (BR) were taken forward for critical and statistical
analysis. All three therapies were effective in increasing the overall survival (OS) and
progression-free survival of elderly/unfit patients with MCL. However, none resulted
in a significant increase in OS compared to R-CHOP. In addition, R-CHOP had a better
toxicity profile when compared to both ibrutinib and BR. We therefore conclude that
treatment of elderly/unfit patients with MCL is still a significant unmet clinical need;
and suggest that outside of the clinical trial setting, R-CHOP should remain the recom-
mended front-line treatment for this patient group.
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1 INTRODUCTION
Mantle cell lymphoma (MCL) was first defined as an aggressive sub-
type of non-Hodgkin’s (NHL) B-cell lymphoma in 1970 and accounts
for around 3% to 6% of B-cell NHLs [1] and is more prevalent in males
than females (4:1). Despite being classified as a distinct entity for over
50 years, MCL remains difficult to treat [2]. The MCL-International
Prognostic Index (MIPI) is used to define the prognosis ofMCLpatients
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[3]. According to theMIPI, patients can be categorised as low risk with
amedian overall survival (OS) rate of 5 years, intermediate riskwithOS
of 51months and high-risk group shows 29months OS rate [1].
MCL is derived from the B-cells in the mantle region of secondary
follicles of lymph nodes [4], and is classically defined by the presence
of a pathognomonic chromosomal translocation t(11;14)(q13;q32) [5].
This translocation results in the fusion of the CCDN1 gene-encoding
cyclin D1 to the immunoglobulin heavy chain promoter, leading to the
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TABLE 1 Current therapies forMCL treatment. Demonstrating their classification and US Food andDrugs Administration (FDA) approval
status [4, 11–20, 21–24]
Therapeutic classification Treatment options









Ibrutinib – 2013 [26]
Acalabrutinib – 2017 [11]
Zanubrutinib – 2019 [12]
Immunotherapy Rituximab 1997 [27]
Lenalidomide (analogue of thalidomide) 2013 [28]
Chemotherapy Bendamustine 2008 [15]
Chlorambucil Still undergoing clinical trials. [29]
Chemo-immunotherapy R-CHOP (rituximab, cyclophosphamide,
doxorubicin, vincristine, prednisone)
∙ Variations of R-CHOP
VR-CAP (bortezomib, rituximab,
cyclophosphamide, doxorubicin, prednisone
Maxi-R-CHOP (higher CHOP doses, followed by







R-CHOP –Addition of rituximab to CHOP
therapy. [30]
VR-CAP – Phase III trials. [31]
Maxi-R-CHOP –Current R-CHOP regimewith
added high doses of cytarabine – Phase II trial.
[16]
R-hyperCVAD –Currently still undergoing
clinical trials. [32]
VcR-CVAD –Currently still undergoing clinical
trials. [33]
BR (bendamustine, rituximab) BR – Phase III trials. *Trial has been completed,
awaiting FDA approval. [34]
Cytarabine-based induction Cytarabine-based induction – Phase III trials. [7]
overexpression of cyclin D1 [6]. The biological functions of cyclin D1
include regulation of transcription, induction of chromosomal insta-
bility and modulation of epigenetic mechanisms [2]. However, not all
MCL cells express cyclin D1 [7]. This has led to the identification of
other genetic factors that may be of importance in MCL such as the
transcription factor SOX11 which is expressed in approximately 90%
of MCL cases; and can be used as a useful diagnostic marker to iden-
tify both cyclin D1-positive and D1-negative MCL [7, 6]. Based on
the clinical presentation and molecular composition, MCL has been
divided into two subtypes; nodal patients who have lymphadenopa-
thy and non-nodal MCL who do not have enlarged lymph nodes [8].
NodalMCL is themost commonvariant comprising approximately 80%
of cases. The malignant lymphocytes from this subtype have overex-
pression of SOX11 and an un-mutated IGHV genotype [9]. Although
lymphadenopathy, splenomegaly and gastrointestinal infiltration are
the most prevalent symptoms in patients with MCL [6], 10–20% of
patients present without these clinical features. The malignant lym-
phocytes in these non-nodal MCLs do not express SOX11 and exhibit
hypermutated IGHV genotype [9]. Taken together, the addition of cyclin
D1, SOX11, and IGHV analysis has broadened criteria for the accurate
diagnosis of MCL which is useful in the selection of the most appropri-
ate treatment. In addition, MCL B cells are defined by expression of
CD5, CD19, CD20 and CD22; and the surface immunoglobulins IgM
and IgD.
This heterogeneity of MCL, together with the fact that patients
respond poorly to therapy, means that a variety of different thera-
peutic treatments have been trialled. These vary in toxicity, disease
targets and mechanism (Table 1). For fit and healthy individuals, allo-
geneic stemcell transplantation (allo-SCT) is routine [10].More intense
drug regimens such as maxi-R-CHOP, involving cytarabine, have also
resulted positive therapy responses in young-fit patients [10]. How-
ever, the MCL population is mostly over the age of 68 and generally
cannot tolerate intense therapeutic regimens or transplantation [2].
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisolone) is the current recommended treatment for individ-
uals ineligible for intense treatments [22]. It is reasonably toler-
ated, in comparison to other therapeutics. The various components
of CHOP contribute to its effectiveness in different ways; but all
result in an inhibition of cell division and/or cell death. The major
mechanism of action of cyclophosphamide (C) is due to its hydroper-
oxide metabolite, 4-hydroperoxycyclophosphamide (4-HC), an inter-
strand DNA cross-linking agents which leads to DNA damage [35].
Doxorubicin (H) also found to play a key role in DNA damage by
inserting itself between DNA bases which results in cell death [36].
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F IGURE 1 Mechanisms of action of rituximab and ibrutinib.
Vincristine (O), on the other hand, binds to the protein tubulin
and inhibits cell duplication; and prednisolone (P) is a corticosteroid
[37]. The addition of rituximab, an anti-CD20 antibody, to the previ-
ous standard treatment, CHOP, enabled an increased response and
OS [27].
The human CD20 protein is a membrane-embedded molecule
express on the surface of B cells including those of MCL [1]. To date,
its role in B-cell receptor (BCR) signalling is not fully understood [38].
Despite its function not being fully elucidated, the expression of CD20
on B-NHL cells led to the molecule being targeted as a therapeutic
approach (Figure 1 [19]). Rituximab is a chimeric monoclonal anti-
body which binds CD20 expressing cells [39], and is thought to act by
inducing antibody-dependent cellular cytotoxicity (ADCC) within the
malignant B cells [40]. Natural killer (NK) cells produce IFNγ, when in
contact with the CD20 positive cells that have bound with rituximab.
Both direct apoptotic and indirect mechanisms involving constituent
immune effector cells can contribute to ADCC [41, 42]. Rituximab can,
consequently, be a successful treatment againstMCL.However, aswith
all therapeutics, R-CHOP is linked with toxicities including peripheral
neuropathy, myelosuppression and cardiac toxicities further restrict-
ing treatment in the elderly/infirm treatment groupwith their multiple
comorbidities [43]. Therefore, other front-line treatment options are
required.
The alkylating agent, bendamustine, has been used in combination
with rituximab as an alternative approach, and has displayed promis-
ing antineoplastic effects, resulting in the potential for bendamustine-
rituximab (BR) therapy to be used as an alternative first-line treatment
to R-CHOP [44]. Despite the fact that the precise mechanism of action
of bendamustine is still poorly understood, it is known to cause signifi-
cant DNA damage [45]. However, secondary mechanisms of action are
also thought to contribute, these include: (1) ineffective DNA repair,
(2) suppression of p53-dependent DNA-damage stress response and
(3) suppression of mitotic checkpoints; all of these events contribute
tomitotic catastrophe and apoptosis [46].
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Although R-CHOP significantly improves initial symptoms and
life expectancy, treatment failure is inevitable leading to relapsed
or refractory MCL [18, 47]. Consequently, a second approach is
required. The most frequent second-line option is to target the BCR
pathway with ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor
(Figure 1 [20, 8]).
The BCR pathway plays an important role in normal and neoplas-
tic B cells. In normal B cells, the BCR signalling pathway is initiated
via antigen binding to surface immunoglobulin resulting in the phos-
phorylation of CD79A and CD79B [14]. This leads to the phosphory-
lation of BTK and phosphatidylinositide-3-kinase-δ (PI3Kδ) and acti-
vation of downstream signal pathways involving mitogen-activated
protein kinase (MAPK), mammalian target of rapamycin (AKT/mTOR),
nuclear factor of activated T cells (NFAT) and nuclear factor kappa
B (NF-κB) [47]. BTK-mediated signalling is involved the growth,
motility adhesion and proliferation of both healthy and malignant
B cells [48].
With regard to MCL, the malignant lymphocytes have constitutive
BCR signalling which is crucial to the pathogenesis of the disease,
and as a result, BTK signalling is unregulated [10]. Ibrutinib binds to
BTK, blocking its phosphorylation and thereby downstream signalling
events (Figure 1 [10]). After administration ibrutinib is metabolised,
CYP3A and CYPRD6, its active metabolite, then forms an irreversible
covalent bond to the cysteine residue 481 on the BTKmolecules, alter-
ing modification of tyrosine 223 on exon 8 [17, 49]. This interrupts
BCR signalling, and disrupts the MCL cell survival and disease pro-
gression. The BTKC481S mutation has been shown to lead to resistance
and treatment failure in CLL; however, this mutation does not play a
role in the primary or acquired resistance to ibrutinib which is seen in
MCL patients [21]. Ibrutinib has also been shown to inhibit off-target
kinases, which may result in the toxicity that limits its overall clinical
benefit [20].
Following ibrutinib treatment, initial response rates are favourable
in most patients. However, all participants ultimately experience resis-
tance to treatment within an average of 6–10 months [17]. One of
the mechanisms of resistance is kinome-adaptive reprogramming [5,
10]. This leads to the activation of the PI3K/AKT/mTOR pathway and
integrin-β1 signalling and results in proliferation and increased adhe-
sion of MCL stromal cells [10]. Adhesion within the stromal micro-
environment mediated by the integrin α4β1 and the chemokine recep-
tors CXCR4 and CXCR5 has been demonstrated to be involved in drug
resistance [50]. In addition, integrins and chemokines play an impor-
tant role in the pathogenesis of MCL and are responsible for direct-
ing and maintaining the malignant MCL cells in a permissive micro-
environmental niche within lymphoid tissues [51]. Another signalling
pathway up-regulated in resistant MCL cells is that of the transcrip-
tion factor NF-κB pathway. The NF-κB pathway also promotes the cell
growth and survival of MCL cells. This protection is mediated, in part,
through the up-regulation of tumorigenic cytokines [21, 50].
In conclusion, MCL is highly aggressive, incurable form of NHL.
Whilst current treatments partially limit tumorigenesis and suppress
disease symptoms, the duration of remission is short and all patients
eventually relapse [2,21,52]. The aim of this systematic review is to
identify which of the currently available therapeutics provide the best
option for treating elderly and unfit patients; taking into account both
survival benefit and the toxicities of the drugs – an important fac-
tor when considering this patient group. A systematic review of the
available data enables us to identify the best treatment options for
patients suffering from MCL that cannot endure intense treatment or
allogeneic stem cell transplant (allo-SCT).
2 METHODS
2.1 Criteria for search
This systematic review was formulated through specific inclusion cri-
teria to identify therapeutic regimens used to treat elderly or unfit
MCL patients (hereafter referred to as elderly/unfit). The analysis
was performed via the electronic database PubMed, with a limit for
extraction between the years 2013 and 2020. The start date was
chosen as the tyrosine kinase inhibitor ibrutinib, a promising new
drug for the treatment of elderly/unfit MCL was first in used in
2013 [53]. Publications were identified using a combination of search
terms covering a broad area in order to ensure that all publications
relevant to the research question were identified. These included:
‘Mantle cell lymphoma treatment’; ‘Mantle cell lymphoma therapy’
and ‘B-cell non-Hodgkin’s lymphoma, including mantle cell lymphoma’.
Nine hundred and one articles were identified using these terms; the
articles had contrasting study designs, including retrospective, ran-
domised,multicentre, observational, cohort, real world, open-label and
prospective.
The identified papers were therefore screened according to the
preferred reporting items for systematic reviews and meta-analyses
(PRISMA). Papers were then analysed on population, interventions,
observations and study design (PIOS) to remove papers which had
insufficient data orwere not representative of the disease demograph-
ics. Phase III studieswere includedwithin these criteria if theywere in a
clinical setting and the treatments had subsequently been approved by
the Food andDrugAdministration (FDA). This screening enabled inclu-
sion of all treatments in current clinical practice outside of the trial set-
ting. The detected articles were extracted for duplicates and further
analysed through title and abstract screening. The final papers under-
went additional inspection with regard to the exclusion criteria (Fig-
ure 2).
With regard to inclusion criteria, since not all unfit patients are
elderly, papers regarding unfit subjects under the age of 65were incor-
porated if the treatment was well tolerated. As MCL is also more
prevalent in males than females (a 4:1 ratio), studies that did not
reflect this bias were also excluded to ensure that the studies taken
forward for analysis accurately represented the patient the popula-
tion. MCL is a relatively rare lymphoma, and therefore large patient
databases were not always available. However, studies with small sam-
ple size (n < 10) were removed to minimise the incorporation of bias.
With regard to therapy inclusion criteria, papers which focused on
transplantation were excluded because elderly/unfit individuals are
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F IGURE 2 Selection criteria for systematic review. Papers were screened according to PRISMA. PIOSwas then used to exclude papers with
insufficient data and those which did not represent the patient demographics
not able to tolerate the intense treatment regimens required prior to
allo-SCT. Finally, papers which looked at B-NHL treatment including
MCL were removed, if the data did not include separate data on MCL
patients.
2.2 Data extraction and analysis
Data extraction was performed from the finalised list of papers. Study
design, sample size, study setting, average length of follow-up, partici-
pant characteristics (age, gender, stage) and outcomes/findings regard-
ing OS, progression-free survival (PFS) and adverse events (AEs) were
extracted. Due to the variation in reporting methods for age, OS, PFS
and AEs we were unable to perform meta-analysis on this data; there-
fore, qualitative assessment was performed. However, wewere able to
perform sufficient data extraction to performmeta-analysis on patient
stage and gender (percentage of males). This enabled us to assess
whether or not the different treatment regimens we examined were
used to treat patients with similar characteristics.
2.3 Statistical analysis
Meta-analysis of patient stage and gender was performed by plotting
the percentages reported for each study with error bars calculated
assuming binomial distribution of the data as:
1.96 +
√
(p ∗ (1 − p) ∕n) ,
where p is the percentage of males or stage and n is the sample size in
the study.
For analysis between treatment groups, firstly, the harmonic mean
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Theω’s are proportional to the sample size and add up to 1










3.1 Description of included studies
The PRISMA diagram for selection of studies in shown in Figure 2. The
original total of records from the PUBMED database search was 1071
articles. Following removal of duplicate papers, 901 papers remained;
of these 805 articles were removed after the titles and abstracts were
screened, leaving 66 articles for full screening. From these papers, 16
articles met all the inclusion criteria, and were taken forward for qual-
itative synthesis (Table 2 [13, 23, 24, 32, 54, 55, 56, 57, 59, 58–61, 63,
64, 65, 67]).
Eight papers involved the use of chemo-immunotherapy in these
papers R-CHOP were compared with BR (four papers), VR-CAP (one
paper) or Aca-C (one paper). For one of the papers which compared R-
CHOP with BR, there was no data for age or percentage of males for
the latter, and the data on BR therefore were not included in subse-
quent analysis as it did not meet the PIOS criteria. In addition, VR-CAP
andAra-Cwerenot tolerated in elderly patients, so data on these treat-
ments did not form part of our subsequent analysis. Five papers exam-
ined kinase inhibitor therapy using ibrutinib.
The main aim of this systematic review was to compare the efficacy
of the different treatment regimens used for unfit/elderly patientswith
MCL; however, there was insufficient data to perform qualitative anal-
ysis of the survival data (Table 2). Therefore, qualitative assessment
was used to assess the efficacy of the current treatment options avail-
able for elderly/unfit patients withMCL. Of these papers, 11 had suffi-
cient data on stage and gender to enable quantitative meta-analysis to
be performed (Table 2).
3.2 Description of study characteristics
Toanalyseandcompare thedata regarding thedifferent treatment reg-
imens, we began by analysing whether, or not, the characteristics of
the patients used in the different studies were the same. Firstly, we
analysed the stage of the patients entered in each of the studies. The
majority of the patients were in stage III/IV across all the data sets
(Figure 3A). However, a lower percentage of cases in stage III/IV was
seen in the studies undertaken in papers 13, 15 and 10 [13, 24, 59]. In
addition, when comparing between the therapies, the stage of patients
treated with BRwas significantly lower than that of those treated with
R-CHOP or ibrutinib (Figure 3B).
Wenext analysed the average ageof the patients in eachof the stud-
ies (Figure 3C). The age range of the patients varied between the differ-
ent studies; some concentrated on elderly patients (papers 3 & 5 [33,
61]),whereas themajority of the studies includedbothelderly andunfit
patients; there was no age range data for study 17 [63]. However, the
median age of the patients from each of the studies was in their 60s
apart frompaper 13where themean agewas late 50s, and papers 3, 16
and 17which were early 70s [33, 66, 63] (Figure 3D).
Finally, we compared the percentage of males in each study; MCL
has a male to female bias of 3–4:1. We therefore compared the per-
centage of males in each study taking into account the sample size.
The percentage of males was comparable across most of the studies
(Figure 3D), apart from paper 13 [13] where the number was signifi-
cantly lower than the reported ratio, and paper 14 [24] where it was
significantly higher. No age range was reported for study 17 [63]. We
then compared the percentage of males between the different thera-
pies (Figure 3E), and this indicated that the studies involving BR had
a significantly lower percentage of males than those using R-CHOP or
ibrutinib.
Taken together, these data indicate that the patient characteristics
of BR patients were significantly different from patients treated with
R-CHOP or ibrutinib with regard to stage and the proportion of males.
The fact that there are less patients with stage III/IV is particularly
important in analysing the outcome data, as high stage predicts a less
favourable response to therapy [52].
3.3 Description of treatment responses
The efficacy of any treatment is determined by two metrics, survival
data and toxicity of the treatment; the latter will be described in the
next section. With regard to survival, PFS and OS were assessed in
most of the studies, in some this was reported as % of patients in each
group at a certain time point, and in others as the average number of
months following treatment (Table 2). There was insufficient data to
analyse the OS between the different treatment regimens; however,
PFS is a good indicator of the efficacy of the treatment [67]. We there-
fore compared the PFS of the different treatment regimens.
Dataon thenumberofmonthsofPFSwereavailable for4/8patients
treated with R-CHOP, 2/4 with BR and all 5 studies with ibrutinib.
The range of PFS between the different studies was similar for all
treatments; R-CHOP 14–32 m; ibrutinib 13–27 m; BR 13–35 m (Fig-
ure 4A). The similarity of the survival ranges for the three treatments
was reflected by the fact that when the average PFS for each treat-
mentwas calculated, thePFS forR-CHOP,BRand ibrutinibwasapprox-
imately 2 years (Figure 4B).
3.4 Description of side effects
With regard to the tolerability of the different treatments, both the
severity of theAEs and the number of patientswho discontinued treat-
ment due to side effects contribute to this metric. Data on patients
who had serious (≥ grade 3) toxicities were reported in 10 of the stud-
ies (Table 2). The most common serious AEs with all treatments were








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































F IGURE 3 Patient demographics. Stage of disease (A) data from individual papers and (B) pooled data. Age of patient group (C) average age
and (D) age range. %males; (E) data from individual papers and (F) pooled data. Ranges in (A), (B), (D) and (F) assume a binomial distribution; in (D),
the actual age range is used. Circles represent themedian values (B). * p< 0.05

















































F IGURE 4 Progression free survival: (A) Data from individual papers and (B) pooled data
haemic; these appeared to be more severe in patients treated with BR.
Of note was the fact that between 6% and 9% of patients treated with
ibrutinib suffered from atrial fibrillation (≥ grade 3), which in some
cases led to death. The discontinuation rate due to toxicity was high
with both ibrutinib (≤25%) [24, 63] and with BR≤16% [61]; no data
were reported for R-CHOP.
4 DISCUSSION
To our knowledge, this is the first systematic review of treatment
options for elderly/unfit patients with MCL. Our study identified five
different treatment regimens which had been examined within the cri-
teria of this review: elderly/unfit patients after the introduction of ibru-
tinib in 2012. The three most frequently studied treatments were R-
CHOP (eight studies [13, 23, 33, 55, 56, 60, 61, 65]), ibrutinib (five stud-
ies [24, 54, 59, 63]) and bendamustine (three studies [13, 33, 60]). We
found that treatment outcomes in patients treatedwith R-CHOPwere
not inferior to those with ibrutinib or BR.
The strength of this study is that the data we analysed were unse-
lected, obtained different clinical settings, and in a number of different
countries. Although our data included randomised clinical trial data in
both single and multi-centre studies, as well as retrospective analysis,
this was true for all the treatments systematically reviewed.Moreover,
theoutcomedatawerebroadly similar regardless of the setting, or con-
tinent, where it was acquired. Therefore, we believe that our data give
a real-world perspective on the efficacy of the treatment choices for
elderly patients withMCL.
R-CHOP is the currently approved front-line treatment for elderly
unfit patients outside of the clinical trial setting [7]. Therefore, sev-
eral studies compared the efficacy of new treatment regimens with
R-CHOP. All three studies using BR compared the treatment in
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randomised control studies with R-CHOP. While only one study with
ibrutinib compared it with R-CHOP, this was because the studies with
ibrutinib were generally in patients who had relapsed on R-CHOP.
Although the data presented in the papers did not allow for statistical
analysis of the survival data, the PFS between the different treatment
regimens did not differ. This was true when looking at the range of sur-
vival data between papers, and when averaging the data in the differ-
ent treatment regimens. Thus, the encouraging results of early trials
of ibrutinib in MCL which resulted in ORR rates in the region of 70%
[2,68] did not result in long-term survival benefits. Thismay be because
the malignant cells of MCL patients quickly become resistant to ibru-
tinib by activating alternative pathways which promote their growth
and survival [21, 69]. It is also important to take into consideration
that ibrutinib was rarely used as a front-line option, and the efficacy of
all treatments for MCL decreases as the number of lines of treatment
increases [66, 67, 70]. In theone study that did commenton theefficacy
of ibrutinib when given as a front-line treatment, the OSwas 9.7 years,
as compared with 41.1 mwhen given as second line [66]. The data sug-
gest that ibrutinib given as the front-line treatment might be a better
option for elderly/unfit patientswithMCL than R-CHOP; however, this
would need to be confirmed by further randomised control trials. Of
note recent phase III studies adding rituximab to ibrutinib in CLL have
shown that this does not improve the efficacy of the kinase treatment
[71].
Furthermore, in the case of BR treatment, when analysing PFS data,
it must be noted that patients treatedwith BR had advantageous prog-
nostic features as compared to those treated with R-CHOP and ibru-
tinib. These patients were younger, had less severe disease (fewer
patients with stage III/IV disease) and a lower proportion were males;
a fact which was highlighted in the data analysis of two of the studies
comparing BR and R-CHOP (Flinn et al 2014, [33]). Thus, although the
data suggest that BR therapy was not inferior to R-CHOP, it is impor-
tant to take into consideration that this may not be the case because
of the better demographics of the patients treated with BR. This is
in line with a study completed in the United Kingdom after our data
collection which found that the PFS of elderly/unfit patients treated
in the United Kingdom with BR and R-CHOP was not significantly
different [72].
Another important issue to consider when deciding the best treat-
ment option for MCL is the toxicity profile of the different regi-
mens. This is particularly importantwhen dealingwith the elderly/unfit
patient group who often have multiple comorbidities and are there-
fore less able to tolerate treatment side effects than their younger,
and generally fitter counterparts. AEs were only reported in one study
using R-CHOP where they found a high number of haemic events ≥3
[65] as compared with other studies which found that severe AEs in
elderly/unfit patients with MCL occur in < 5% of patients [2,61]. The
reasons for this discrepancy are unclear but highlight the importance
of comparing data from different sources. As with R-CHOP, the most
common toxicities observed with ibrutinib and BR treatment were
haemic. Patients treated with BR had more severe side effects than
those treated with ibrutinib, although the demographics of the patient
group were more favourable. By contrast, the number of patients who
discontinued BR due to toxicity was higher than those who discontin-
ued ibrutinib, these data were only included in one study of each treat-
ment, and therefore warrant further validation in order to be defini-
tively assessed. Taken together, the data indicate that the toxicity pro-
file ofBR ismore severe than thatof ibrutinib; and thatboth treatments
havemore severe toxicity profiles than R-CHOP.
In conclusion,when taking intoaccount the survival and toxicity pro-
files, R-CHOP still remains the best treatment option for elderly/unfit
patients with MCL. However, as with all treatments available, the
duration of remission following front-line treatment with R-CHOP is
approximately 2 years. Therefore, treatment of elderly/unfit patients
withMCL still remains a clinically unmet need.
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